Aldehyde dehydrogenase 1 (ALDH1) is an NADP+-dependent member of the aldehyde dehydrogenase superfamily that metabolizes exogenously produced aldehydes to alleviate aldehyde stress.1 ALDH1 is expressed as three isozymes, ALDH1A1, ALDH1A2, and ALDH1A3, of which, ALDH1A1 shares greater than 70% sequence homology with ALDH1A2 and ALDH1A3. ALDH1A1 is a cytosolic homotetramer, with each monomer composed of a catalytic domain, an NAD-binding domain, and an oligomerization domain that is widely expressed in brain, liver, kidneys, adipose tissue, retina, and lens. It catalyzes the oxidation of retinaldehyde to retinoic acid, a transcriptional regulator essential for normal cell growth and differentiation.1,2 Tumoral levels of ALDH1A1 are increased and associated with poor prognosis in patients with high clinical stages of nasopharyngeal carcinomas.2 Levels of ALDH1A1 are positively correlated with disease severity in postmortem brain tissue from patients with Alzheimer’s disease.3 ALDH1A1-positive nigrostriatal dopaminergic neurons (DANs) are decreased compared with the number of ALDH1A1-negative nigrostriatal DANs in postmortem brain tissue from patients with Parkinson’s disease.4 Cayman’s ALDH1A1 Monoclonal Antibody (Clone 5G9E6C9) can be used for ELISA, flow cytometry (FC), immunocytochemistry (ICC), immunofluorescence (IF), and Western blot (WB) applications.WARNING This product is not for human or veterinary use.
